Irinotecan

Contraindicated

Irinotecan Atazanavir Reyataz Increased irinotecan and its active metabolite, SN-38 exposure Details Irinotecan Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of infection by the live vaccine Details Irinotecan Cobicistat Tybost Increased irinotecan exposure and an risk of increased irinotecan active metabolite exposure Details Irinotecan Dengue Tetravalent Vaccine, Live An increased risk of infection by the live vaccine Details Irinotecan Ensitrelvir Increased CYP3A/BCRP substrate exposure and an increased risk of adverse reactions Details Irinotecan Itraconazole Sporanox Increased irinotecan exposure Details Irinotecan Ketoconazole Extina Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Measles Virus Vaccine, Live An increased risk of infection by the live vaccine Details Irinotecan Mumps Virus Vaccine, Live An increased risk of infection by the live vaccine Details Irinotecan Rubella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Irinotecan Smallpox Monkeypox Vaccine An increased risk of infection by the live vaccine Details Irinotecan Typhoid Vaccine Typhim VI® An increased risk of infection by the live vaccine Details Irinotecan Varicella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Irinotecan Yellow Fever Vaccine Stamaril An increased risk of infection by the live vaccine Details Irinotecan Ketoconazole Topical Extina® Foam Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details

Major

Irinotecan Abametapir Increased exposure of CYP3A4 substrate Details Irinotecan Asciminib Scemblix Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse effects Details Irinotecan Capmatinib Tabrecta Increased BCRP substrate exposure and an increased risk of adverse reactions Details Irinotecan Darolutamide Nubeqa Increased plasma concentrations of BCRP substrates Details Irinotecan Enasidenib Idhifa Increased exposure of BCRP substrate Details Irinotecan Gemfibrozil Lopid Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine Details Irinotecan Adenovirus Vaccine Type 7, Live An increased risk of infection by the live vaccine Details Irinotecan Apalutamide Erleada Reduced irinotecan exposure and reduced irinotecan active metabolite exposure Details Irinotecan Avacopan Tavneos Increased CYP3A4 substrate exposure Details Irinotecan Boceprevir Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Carbamazepine Carbatrol Reduced irinotecan exposure and reduced irinotecan active metabolite exposure Details Irinotecan Ceritinib Zykadia Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Cholera Vaccine Ipol An increased risk of infection by the live vaccine Details Irinotecan Clarithromycin Biaxin Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Conivaptan Vaprisol Increased CYP3A substrate exposure Details Irinotecan Danicopan Voydeya Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse effect Details Irinotecan Darunavir Increased irinotecan exposure and an increased risk of irinotecan-related adverse events Details Irinotecan Ebola Zaire Vaccine, Live An increased risk of infection by the live vaccine Details Irinotecan Eltrombopag Alvaiz Increased irinotecan exposure and an increased risk of irinotecan-related adverse reactions Details Irinotecan Enzalutamide Xtandi Reduced irinotecan exposure and reduced irinotecan active metabolite exposure Details Irinotecan Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Irinotecan Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Irinotecan Fexinidazole An increased CYP3A4 substrate exposure Details Irinotecan Fosnetupitant Increased exposure to chemotherapy agent and increased risk of side effects Details